SCHEMBL7120480

SCHEMBL7120480

O=S(=O)(Nc1ccc(OC2CCN(c3ccncc3)CC2)cc1)c1ccc2cc(Br)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
F10 P00742 6/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LSS P48449 1/20 0.41
PGR P06401 2/20 0.39
LMNA P02545 2/20 0.39
PKM P14618 1/20 0.39
GFER P55789 1/20 0.39
PLAU P00749 1/20 0.39
HTR1A P08908 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633771 0.90 KMT2A (0.59) KMT2AMEN1MAPTALDH1A1F10
SCHEMBL7124112 0.90 F2 (0.46) KMT2AMEN1MAPTALDH1A1F10
SCHEMBL7115867 0.88 CYP3A4 (0.47) KMT2AMEN1MAPTALDH1A1F10
SCHEMBL5632447 0.87 LSS (0.44) MAPTF10SMN1; SMN2LSS
SCHEMBL6578432 0.86 F10 (0.46) KMT2AMEN1MAPTALDH1A1F10
SCHEMBL7119668 0.83 F10 (0.42) F10LSS
SCHEMBL5632556 0.83 ALDH1A1 (0.56) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL5632013 0.81 LMNA (0.47) KMT2AMEN1MAPTALDH1A1PGR
SCHEMBL5632729 0.81 F2 (0.55) KMT2AMEN1MAPTALDH1A1F10
SCHEMBL9760149 0.78 IDO1 (0.45) MAPTSMN1; SMN2CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207882-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED 2003-11-06 US claimed
US-20030207882-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207882-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents F2, SERPINC1, F11 KMT2A 2234/4885MEN1 594/4885MAPT 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.